NCT06663969 Evaluating Modulation Effects of Temporal Interference Using SEEG
| NCT ID | NCT06663969 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xuanwu Hospital, Beijing |
| Condition | Deep Brain Stimulation |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-11-04 |
| Primary Completion | 2025-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2024-11-04 with a primary completion date of 2025-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This single-center prospective study aims to investigate the electrophysiological mechanisms of temporal interference (TI) in humans by analyzing clinical, imaging, and electrophysiological data from patients aged 14-60 with drug-resistant epilepsy.
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of drug-resistant epilepsy; * No severe systemic diseases; * Implantation of stereotactic electrodes; * Agreement to participate in this study and signs the informed consent form. Exclusion Criteria: * Hematoma at the scalp electrode site or fluid accumulation under the electrode after intracranial electrode placement.
Contact & Investigator
Liankun Ren, MD
PRINCIPAL INVESTIGATOR
Xuanwu Hospital, Beijing
Frequently Asked Questions
Who can join the NCT06663969 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, up to 65 Years, studying Deep Brain Stimulation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06663969 currently recruiting?
Yes, NCT06663969 is actively recruiting participants. Contact the research team at renlk2022@outlook.com for enrollment information.
Where is the NCT06663969 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06663969 clinical trial?
NCT06663969 is sponsored by Xuanwu Hospital, Beijing. The principal investigator is Liankun Ren, MD at Xuanwu Hospital, Beijing. The trial plans to enroll 20 participants.